Navigation Links
PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
Date:5/30/2012

BOSTON, May 30, 2012 /PRNewswire/ -- Today, in conjunction with its Investor Day being held tomorrow in New York City, PAREXEL International Corporation (Nasdaq: PRXL) announced forward-looking earnings expectations for the fourth quarter of Fiscal Year 2012 (ending June 30, 2012), for Fiscal Year 2012, and for Fiscal Year 2013. 

The Company reconfirmed its guidance for the fourth quarter of Fiscal Year 2012 and for all of Fiscal Year 2012, as issued in a press release dated April 30, 2012.  To reiterate, for the fourth quarter of Fiscal Year 2012, the Company anticipates reporting consolidated service revenue in the range of $376.0 to $381.0 million, and diluted earnings per share as reported under Generally Accepted Accounting Principles (GAAP) of $0.28 to $0.30.  For Fiscal Year 2012 (ending June 30, 2012), the Company continues to expect consolidated service revenue to be in the range of $1.380 to $1.385 billion, GAAP earnings per diluted share to be $1.03 to $1.05, and adjusted earnings per diluted share to be in the range of $1.04 to $1.06.   Adjusted numbers exclude the impact of restructuring-related charges and certain Q3 FY12 tax benefits, as previously described in the April 30th press release. 

The Company is providing guidance estimates for Fiscal Year 2013 for the first time, and anticipates reporting consolidated service revenue in the range of $1.625 to $1.655 billion, and GAAP earnings per diluted share of $1.31 to $1.47.

Those who wish to listen to the Company's Investor Day presentations and to view the accompanying slides should log onto the Company's website at www.PAREXEL.com and click on the PAREXEL Investor Day link under the "Upcoming Events" section of the Investors homepage at least 15 minutes prior to the event's broadcast which will start at 8:30 a.m. ET.  Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed.  In addition, an archived version of the event's presentations will be located in the Investor Relations section of PAREXEL's website.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 as filed with the SEC on May 10, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

CONTACTS:

James Winschel, Senior Vice President and Chief Financial Officer


Jill Baker, Corporate Vice President of Investor Relations


+1-781-434-4118


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
2. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
3. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
4. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
5. PAREXEL Announces Date of Third Quarter Fiscal Year 2012 Earnings Release and Conference Call
6. PAREXEL to Address New Regulatory Guidelines and Data Standards at DIA EuroMeeting
7. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
8. PAREXEL International to Present at Barclays Capital Healthcare Conference
9. PAREXEL International to Present at Cowen Healthcare Conference and Raymond James Investors Conference
10. PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives
11. PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition ... for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics ... HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded studies ...
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America (BPC), ... reputable physician in their area, announces the launch of a new and proprietary customer ... are looking for reputable physicians to help them with back or neck pain and ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):